{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:26:25Z","timestamp":1774311985690,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T00:00:00Z","timestamp":1723939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CPT Pharmacom &amp; Syst Pharma"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Valemetostat is an oral inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1 approved in Japan for the treatment of adult T\u2010cell leukemia\/lymphoma (ATLL). To support the approved daily dose of 200\u2009mg and inform dose adjustments in patients with ATLL, Bayesian exposure\u2013response analyses were conducted using data from two clinical trials. The analyses included two efficacy endpoints, overall response by central and investigator assessments in patients with ATLL (<jats:italic>n<\/jats:italic>\u2009=\u200938, 150\u2013200\u2009mg), and six safety endpoints in patients with non\u2010Hodgkin lymphoma (<jats:italic>n<\/jats:italic>\u2009=\u2009102, 150\u2013300\u2009mg), which included grade \u22653 laboratory values for anemia, absolute neutrophil count decreased, and platelet count decreased; any grade \u22653 treatment\u2010emergent adverse event (TEAE); and dose reductions and dose interruptions due to TEAEs. A slightly positive relationship was observed between unbound exposure and efficacy endpoints. A steeper relationship was observed in safety endpoints, compared with efficacy. Candidate covariate effects, except intercepts of the baseline laboratory values, were regularized via spike and slab priors in a Bayesian framework; only the laboratory values for corresponding hematologic TEAEs were shown to be of substantial impact. The target exposure range was established by defining a modified region of practical equivalence (184\u2013887\u2009ng\u00b7h\/mL), which was expected to provide satisfactory efficacy and acceptable safety within the range of available exposure data. The simulated exposure range considering inter\u2010individual variability showed that 200\u2009mg could reach target exposure in the overall population and across subpopulations of interest, supporting the use of valemetostat 200\u2009mg in patients with ATLL.<\/jats:p>","DOI":"10.1002\/psp4.13203","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T06:38:26Z","timestamp":1724049506000},"page":"1655-1669","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bayesian sparse regression for exposure\u2013response analyses of efficacy and safety endpoints to justify the clinical dose of valemetostat for adult T\u2010cell leukemia\/lymphoma"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0206-2956","authenticated-orcid":false,"given":"Masato","family":"Fukae","sequence":"first","affiliation":[{"name":"Daiichi Sankyo Co., Ltd.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2363-1339","authenticated-orcid":false,"given":"James","family":"Rogers","sequence":"additional","affiliation":[{"name":"Metrum Research Group  Tariffville Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3223-8251","authenticated-orcid":false,"given":"Ramon","family":"Garcia","sequence":"additional","affiliation":[{"name":"Metrum Research Group  Tariffville Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Tachibana","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co., Ltd.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co., Ltd.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,8,18]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2017.021907"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017011106"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0658-4"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6198"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13655"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.10.083"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.968780"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-662593"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01800-5"},{"key":"e_1_2_11_12_1","unstructured":"Daiichi Sankyo Tokyo Japan.EZHARMIA\u00ae (valemetostat tosilate). [package insert].2022."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016862"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179301"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1993.10476353"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.2428"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1315"},{"key":"e_1_2_11_18_1","first-page":"1","article-title":"Population pharmacokinetics of total and unbound valemetostat and platelet dynamics in healthy volunteers and patients with non\u2010Hodgkin lymphoma","author":"Fukae M","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v080.i01"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1201\/9780429029608"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1214\/08-AOAS191"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1214\/17-EJS1337SI"},{"key":"e_1_2_11_23_1","volume-title":"Bayesian Data Analysis","author":"Gelman A","year":"2004"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/10618600.1996.10474708"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011555016423"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v076.i01"}],"container-title":["CPT: Pharmacometrics &amp; Systems Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.13203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T13:39:34Z","timestamp":1729604374000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/psp4.13203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,18]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1002\/psp4.13203"],"URL":"https:\/\/doi.org\/10.1002\/psp4.13203","archive":["Portico"],"relation":{},"ISSN":["2163-8306","2163-8306"],"issn-type":[{"value":"2163-8306","type":"print"},{"value":"2163-8306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,18]]},"assertion":[{"value":"2024-03-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}